OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has announced that it has selected chronic pouchitis and hidradenitis suppurativa (HS) as new key indications for lusvertikimab, a potential first-in-class IL-7R antagonist.
According to OSE, these indications were selected based on strong, IL-7R-driven biology and are fully aligned with the company’s 2026–2028 strategic plan to expand lusvertikimab into targeted, high value immune-mediated diseases. Development of one or both indications will proceed subject to financing, with the first Phase 2 clinical trial planned to initiate in H2 2026.
In a statement, Marc Le Bozec, CEO of OSE, commented, “We selected pouchitis and HS because both indications present compelling scientific rationale for lusvertikimab, which could become the first-in-class IL-7R antagonist to reach the market. Pouchitis is a natural extension of our ulcerative colitis work and, due to its well-defined population, represents a raredisease opportunity we can advance independently at a reasonable cost. HS, by contrast, is a much larger dermatology indication where we can move quickly toward a proof-of-concept readout with a highly differentiated asset. Our goal is to initiate a first Phase 2 study in the second half of 2026, subject to financing. Together, these indications reinforce our strategy and strengthen the long-term potential of lusvertikimab as a differentiated immunology platform with multi-billion peak sales potential.”
